Loading…

Laparoscopic Versus Open Transperitoneal Nephrectomy for the Treatment of Giant Hydronephrosis

Objective: To assess the effectiveness of laparoscopic transperitoneal nephrectomy in the treatment of patients with giant hydronephrosis and to compare the results with open nephrectomy. Materials and Methods: We reviewed the data of 19 patients underwent laparoscopic (laparoscopic group, n=8) and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of urological surgery 2020-12, Vol.7 (4), p.276-280
Main Authors: Demirdağ, Çetin, Çitgez, Sinharib
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To assess the effectiveness of laparoscopic transperitoneal nephrectomy in the treatment of patients with giant hydronephrosis and to compare the results with open nephrectomy. Materials and Methods: We reviewed the data of 19 patients underwent laparoscopic (laparoscopic group, n=8) and open (open group, n=11) transperitoneal nephrectomy for giant hydronephrosis between January 2008 and 2018. Demographic characteristics, clinical, laboratory and radiological findings of cases were examined. Perioperative and postoperative outcomes were reported. Mann-Whitney U and Fisher’s Exact tests were used in the statistical analysis. Results: The mean operation time was 112.5±19.1 (90-140) minutes and 107.2±19.1 (80-140) minutes, respectively, for the laparoscopic and open groups (p=0.546). The mean hospitalization period was 3.5 (3-7) and 6 (5-8) days, respectively, for the laparoscopic and open approach (p=0.003). No major complications during the perioperative period were observed in any of the patients. The mean follow-up periods were 36 (6-60) and 70 (39-80) months, respectively, for the laparoscopic and open groups (p=0.000). Conclusion: Laparoscopic transperitoneal nephrectomy appears to be equally effective to the open approach with a shorter hospitalization period for the treatment of giant hydronephrosis. It may be offered as a safe and acceptable model of treatment for patients presenting with giant hydronephrosis.
ISSN:2148-9580
2148-9580
DOI:10.4274/jus.galenos.2020.3279